表紙:バイオサージェリー (バイオ手術) の世界市場
市場調査レポート
商品コード
893777

バイオサージェリー (バイオ手術) の世界市場

Biosurgery

出版日: | 発行: Global Industry Analysts, Inc. | ページ情報: 英文 139 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=135.89円
バイオサージェリー (バイオ手術) の世界市場
出版日: 2021年04月01日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 139 Pages
納期: 即日から翌営業日
● ご注意事項
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

当レポートでは、世界のバイオサージェリー (生物学的外科処置) 市場について分析し、全体的な市場規模の実績値・予測値や、主な市場促進・抑制要因、今後の市場成長の方向性、各地域・主要国の市場の詳細動向などを調査すると共に、主要企業のプロファイルしております。

第1章 分析手法

第2章 エグゼクティブ・サマリー

  • 市場概要
  • 代表的企業の分析
  • 市場の動向と促進要因
  • 世界市場の将来展望
    • 市場規模の動向見通し:地域別/国別
    • 手術用シール材
      • 市場規模 (過去9年間・今後8年間分)
    • 止血剤
    • 癒着防止剤
    • 軟組織管理
    • 代替骨移植片

第3章 市場分析

  • 地域別の市場分析
  • 米国
    • 市場の基本データ
    • バイオサージェリーの市場規模 (実績値・予測値)
    • 製品別の市場規模 (実績値・予測値)
  • カナダ
  • 日本
  • 中国
  • 欧州
    • フランス
    • ドイツ
    • イタリア
    • 英国
    • その他
  • アジア太平洋地域
  • 他の国々 (RoW)

第4章 企業

  • B. BRAUN MELSUNGEN AG
  • BARD, A BECTON, DICKINSON COMPANY
  • BAXTER INTERNATIONAL
  • COHERA MEDICAL
  • CRYOLIFE
  • HEMOSTASIS
  • INTEGRA LIFESCIENCES HOLDINGS CORPORATION
  • JOHNSON & JOHNSON
  • MAQUET HOLDING B.V. & CO. KG
  • MEDTRONIC PLC
  • PFIZER
  • SANOFI US
  • STRYKER CORPORATION

第5章 関連分析

目次
Product Code: MCP10738

Abstract:

Global Biosurgery Market to Reach $16.7 Billion by 2027

Amid the COVID-19 crisis, the global market for Biosurgery estimated at US$11.8 Billion in the year 2020, is projected to reach a revised size of US$16.7 Billion by 2027, growing at a CAGR of 5.1% over the analysis period 2020-2027. Surgical Sealing Agents, one of the segments analyzed in the report, is projected to record a 5.9% CAGR and reach US$3 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Hemostatic Agents segment is readjusted to a revised 5% CAGR for the next 7-year period.

The U.S. Market is Estimated at $3.5 Billion, While China is Forecast to Grow at 4.8% CAGR

The Biosurgery market in the U.S. is estimated at US$3.5 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$2.9 Billion by the year 2027 trailing a CAGR of 4.8% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5% and 4% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.1% CAGR.

Anti-Adhesion Agents Segment to Record 5.5% CAGR

In the global Anti-Adhesion Agents segment, USA, Canada, Japan, China and Europe will drive the 5.5% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$453.4 Million in the year 2020 will reach a projected size of US$661.5 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$1.9 Billion by the year 2027.

Select Competitors (Total 46 Featured) -

  • B. Braun Melsungen AG
  • BARD, A Becton, Dickinson Company
  • Baxter International, Inc.
  • Cohera Medical, Inc.
  • CryoLife, Inc.
  • Hemostasis, LLC
  • Integra LifeSciences Holdings Corporation
  • Johnson & Johnson
  • MAQUET Holding B.V. & Co. KG
  • Medtronic PLC
  • Pfizer, Inc.
  • Sanofi U.S.
  • Stryker Corporation

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Biosurgery Market to Witness Steady Growth
    • EXHIBIT 1: Percentage Market Share of Worldwide Bio-Surgeries by Country: 2015 and 2022
    • Bone Graft Substitutes to Account for Largest Share
    • North American Region to Dominate Market Growth
    • EXHIBIT 2: Worldwide Biosurgery Market: Breakdown of Total Sales Value (in Billion USD) by Region: 2015 and 2022
    • Impact of Covid-19 and a Looming Global Recession
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • New Approvals to Support Market Growth
    • Various Strategies from Leading Players to Bolster Market Growth
    • Rapid Growth in Ageing Population Drives Market Growth
    • EXHIBIT 3: Global Population Statistics and Estimates for the 60+ Age Group (1990, 2015, 2050E, 2100E)
    • Rise in Worldwide Surgical Procedures to Fuel Market Growth
    • EXHIBIT 4: Total Number of Surgical Procedures Performed (in Millions) Per Annum in the US: 1981-2015
    • EXHIBIT 5: Total Number of Surgical Procedures Performed for Inpatients in Europe per Annum: 2001-2015
    • Rising Incidence of Injuries due to Trauma Supports Market Growth
    • Myriad Health End-Users to Drive Market Growth
    • EXHIBIT 6: Percentage Breakdown of Biosurgery Market Shares by Application: 2018
    • EXHIBIT 7: Percentage Growth Rate of Various Bio-Surgical Products in Wound-Closure Segment: 2011-2017
    • Innovations to Spur Market Growth
    • EXHIBIT 8: Total Sales of DermaPure: 2016-2018
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Current & Future Analysis for Biosurgery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 2: World Historic Review for Biosurgery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 3: World 15-Year Perspective for Biosurgery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027
    • TABLE 4: World Current & Future Analysis for Surgical Sealing Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 5: World Historic Review for Surgical Sealing Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 6: World 15-Year Perspective for Surgical Sealing Agents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 7: World Current & Future Analysis for Hemostatic Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 8: World Historic Review for Hemostatic Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 9: World 15-Year Perspective for Hemostatic Agents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 10: World Current & Future Analysis for Anti-Adhesion Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 11: World Historic Review for Anti-Adhesion Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 12: World 15-Year Perspective for Anti-Adhesion Agents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 13: World Current & Future Analysis for Soft Tissue Management by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 14: World Historic Review for Soft Tissue Management by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 15: World 15-Year Perspective for Soft Tissue Management by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 16: World Current & Future Analysis for Bone Graft Substitutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 17: World Historic Review for Bone Graft Substitutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 18: World 15-Year Perspective for Bone Graft Substitutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

  • UNITED STATES
    • TABLE 19: USA Current & Future Analysis for Biosurgery by Product - Surgical Sealing Agents, Hemostatic Agents, Anti-Adhesion Agents, Soft Tissue Management and Bone Graft Substitutes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 20: USA Historic Review for Biosurgery by Product - Surgical Sealing Agents, Hemostatic Agents, Anti-Adhesion Agents, Soft Tissue Management and Bone Graft Substitutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 21: USA 15-Year Perspective for Biosurgery by Product - Percentage Breakdown of Value Sales for Surgical Sealing Agents, Hemostatic Agents, Anti-Adhesion Agents, Soft Tissue Management and Bone Graft Substitutes for the Years 2012, 2020 & 2027
  • CANADA
    • TABLE 22: Canada Current & Future Analysis for Biosurgery by Product - Surgical Sealing Agents, Hemostatic Agents, Anti-Adhesion Agents, Soft Tissue Management and Bone Graft Substitutes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 23: Canada Historic Review for Biosurgery by Product - Surgical Sealing Agents, Hemostatic Agents, Anti-Adhesion Agents, Soft Tissue Management and Bone Graft Substitutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 24: Canada 15-Year Perspective for Biosurgery by Product - Percentage Breakdown of Value Sales for Surgical Sealing Agents, Hemostatic Agents, Anti-Adhesion Agents, Soft Tissue Management and Bone Graft Substitutes for the Years 2012, 2020 & 2027
  • JAPAN
    • TABLE 25: Japan Current & Future Analysis for Biosurgery by Product - Surgical Sealing Agents, Hemostatic Agents, Anti-Adhesion Agents, Soft Tissue Management and Bone Graft Substitutes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 26: Japan Historic Review for Biosurgery by Product - Surgical Sealing Agents, Hemostatic Agents, Anti-Adhesion Agents, Soft Tissue Management and Bone Graft Substitutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 27: Japan 15-Year Perspective for Biosurgery by Product - Percentage Breakdown of Value Sales for Surgical Sealing Agents, Hemostatic Agents, Anti-Adhesion Agents, Soft Tissue Management and Bone Graft Substitutes for the Years 2012, 2020 & 2027
  • CHINA
    • TABLE 28: China Current & Future Analysis for Biosurgery by Product - Surgical Sealing Agents, Hemostatic Agents, Anti-Adhesion Agents, Soft Tissue Management and Bone Graft Substitutes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 29: China Historic Review for Biosurgery by Product - Surgical Sealing Agents, Hemostatic Agents, Anti-Adhesion Agents, Soft Tissue Management and Bone Graft Substitutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 30: China 15-Year Perspective for Biosurgery by Product - Percentage Breakdown of Value Sales for Surgical Sealing Agents, Hemostatic Agents, Anti-Adhesion Agents, Soft Tissue Management and Bone Graft Substitutes for the Years 2012, 2020 & 2027
  • EUROPE
    • TABLE 31: Europe Current & Future Analysis for Biosurgery by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 32: Europe Historic Review for Biosurgery by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 33: Europe 15-Year Perspective for Biosurgery by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027
    • TABLE 34: Europe Current & Future Analysis for Biosurgery by Product - Surgical Sealing Agents, Hemostatic Agents, Anti-Adhesion Agents, Soft Tissue Management and Bone Graft Substitutes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 35: Europe Historic Review for Biosurgery by Product - Surgical Sealing Agents, Hemostatic Agents, Anti-Adhesion Agents, Soft Tissue Management and Bone Graft Substitutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 36: Europe 15-Year Perspective for Biosurgery by Product - Percentage Breakdown of Value Sales for Surgical Sealing Agents, Hemostatic Agents, Anti-Adhesion Agents, Soft Tissue Management and Bone Graft Substitutes for the Years 2012, 2020 & 2027
  • FRANCE
    • TABLE 37: France Current & Future Analysis for Biosurgery by Product - Surgical Sealing Agents, Hemostatic Agents, Anti-Adhesion Agents, Soft Tissue Management and Bone Graft Substitutes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 38: France Historic Review for Biosurgery by Product - Surgical Sealing Agents, Hemostatic Agents, Anti-Adhesion Agents, Soft Tissue Management and Bone Graft Substitutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 39: France 15-Year Perspective for Biosurgery by Product - Percentage Breakdown of Value Sales for Surgical Sealing Agents, Hemostatic Agents, Anti-Adhesion Agents, Soft Tissue Management and Bone Graft Substitutes for the Years 2012, 2020 & 2027
  • GERMANY
    • TABLE 40: Germany Current & Future Analysis for Biosurgery by Product - Surgical Sealing Agents, Hemostatic Agents, Anti-Adhesion Agents, Soft Tissue Management and Bone Graft Substitutes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 41: Germany Historic Review for Biosurgery by Product - Surgical Sealing Agents, Hemostatic Agents, Anti-Adhesion Agents, Soft Tissue Management and Bone Graft Substitutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 42: Germany 15-Year Perspective for Biosurgery by Product - Percentage Breakdown of Value Sales for Surgical Sealing Agents, Hemostatic Agents, Anti-Adhesion Agents, Soft Tissue Management and Bone Graft Substitutes for the Years 2012, 2020 & 2027
  • ITALY
    • TABLE 43: Italy Current & Future Analysis for Biosurgery by Product - Surgical Sealing Agents, Hemostatic Agents, Anti-Adhesion Agents, Soft Tissue Management and Bone Graft Substitutes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 44: Italy Historic Review for Biosurgery by Product - Surgical Sealing Agents, Hemostatic Agents, Anti-Adhesion Agents, Soft Tissue Management and Bone Graft Substitutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 45: Italy 15-Year Perspective for Biosurgery by Product - Percentage Breakdown of Value Sales for Surgical Sealing Agents, Hemostatic Agents, Anti-Adhesion Agents, Soft Tissue Management and Bone Graft Substitutes for the Years 2012, 2020 & 2027
  • UNITED KINGDOM
    • TABLE 46: UK Current & Future Analysis for Biosurgery by Product - Surgical Sealing Agents, Hemostatic Agents, Anti-Adhesion Agents, Soft Tissue Management and Bone Graft Substitutes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 47: UK Historic Review for Biosurgery by Product - Surgical Sealing Agents, Hemostatic Agents, Anti-Adhesion Agents, Soft Tissue Management and Bone Graft Substitutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 48: UK 15-Year Perspective for Biosurgery by Product - Percentage Breakdown of Value Sales for Surgical Sealing Agents, Hemostatic Agents, Anti-Adhesion Agents, Soft Tissue Management and Bone Graft Substitutes for the Years 2012, 2020 & 2027
  • REST OF EUROPE
    • TABLE 49: Rest of Europe Current & Future Analysis for Biosurgery by Product - Surgical Sealing Agents, Hemostatic Agents, Anti-Adhesion Agents, Soft Tissue Management and Bone Graft Substitutes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 50: Rest of Europe Historic Review for Biosurgery by Product - Surgical Sealing Agents, Hemostatic Agents, Anti-Adhesion Agents, Soft Tissue Management and Bone Graft Substitutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 51: Rest of Europe 15-Year Perspective for Biosurgery by Product - Percentage Breakdown of Value Sales for Surgical Sealing Agents, Hemostatic Agents, Anti-Adhesion Agents, Soft Tissue Management and Bone Graft Substitutes for the Years 2012, 2020 & 2027
  • ASIA-PACIFIC
    • TABLE 52: Asia-Pacific Current & Future Analysis for Biosurgery by Product - Surgical Sealing Agents, Hemostatic Agents, Anti-Adhesion Agents, Soft Tissue Management and Bone Graft Substitutes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 53: Asia-Pacific Historic Review for Biosurgery by Product - Surgical Sealing Agents, Hemostatic Agents, Anti-Adhesion Agents, Soft Tissue Management and Bone Graft Substitutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 54: Asia-Pacific 15-Year Perspective for Biosurgery by Product - Percentage Breakdown of Value Sales for Surgical Sealing Agents, Hemostatic Agents, Anti-Adhesion Agents, Soft Tissue Management and Bone Graft Substitutes for the Years 2012, 2020 & 2027
  • REST OF WORLD
    • TABLE 55: Rest of World Current & Future Analysis for Biosurgery by Product - Surgical Sealing Agents, Hemostatic Agents, Anti-Adhesion Agents, Soft Tissue Management and Bone Graft Substitutes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 56: Rest of World Historic Review for Biosurgery by Product - Surgical Sealing Agents, Hemostatic Agents, Anti-Adhesion Agents, Soft Tissue Management and Bone Graft Substitutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 57: Rest of World 15-Year Perspective for Biosurgery by Product - Percentage Breakdown of Value Sales for Surgical Sealing Agents, Hemostatic Agents, Anti-Adhesion Agents, Soft Tissue Management and Bone Graft Substitutes for the Years 2012, 2020 & 2027

IV. COMPETITION

  • Total Companies Profiled: 46